266 related articles for article (PubMed ID: 19444783)
41. Investigator financial disclosures and its effect on research subjects.
Gibbs JN; Guagnano GA
Food Drug Law J; 2007; 62(4):727-37. PubMed ID: 18557228
[No Abstract] [Full Text] [Related]
42. The 'apparent' color of money.
Peritt D
Nat Med; 2004 Feb; 10(2):120. PubMed ID: 14760411
[No Abstract] [Full Text] [Related]
43. Industry support and professional medical associations.
Lombardo PC
JAMA; 2009 Aug; 302(7):737-8; author reply 739. PubMed ID: 19690301
[No Abstract] [Full Text] [Related]
44. Conflict of interest in Psychiatry.
Bernardo M; Martín-Carrasco M
Rev Psiquiatr Salud Ment (Engl Ed); 2019; 12(4):201-206. PubMed ID: 31255516
[No Abstract] [Full Text] [Related]
45. Unravelling industry bias in clinical trials.
Gluud LL
Pain; 2006 Apr; 121(3):175-176. PubMed ID: 16513277
[No Abstract] [Full Text] [Related]
46. Assessing 'real science': poor studies, industry ties taking toll.
Hamilton J
J Calif Dent Assoc; 2004 Jan; 32(1):29-39. PubMed ID: 14986742
[No Abstract] [Full Text] [Related]
47. Conflict of interest. Stung by controversy, biomedical groups urge consistent guidelines.
Kaiser J
Science; 2007 Jul; 317(5837):441. PubMed ID: 17656694
[No Abstract] [Full Text] [Related]
48. Making friends with the campus capitalists.
Wingerson L
New Sci; 1982 Dec 23-30; 96(1337-1338):780. PubMed ID: 11655527
[No Abstract] [Full Text] [Related]
49. Proceedings of TCT: TCT Keynote Speaker Addresses conflict of interest.
J Interv Cardiol; 2007 Apr; 20(2):171-2. PubMed ID: 17391228
[No Abstract] [Full Text] [Related]
50. [New conduct recommendations for physicians cooperating with the pharmaceutical industry? The "FS Codex" and its consequences for physicians].
Häser I; Hofmann A
Anaesthesist; 2005 Mar; 54(3):263-7. PubMed ID: 15719243
[No Abstract] [Full Text] [Related]
51. Centers for Disease Control and Prevention: protecting the private good?
Lenzer J
BMJ; 2015 May; 350():h2362. PubMed ID: 25979454
[No Abstract] [Full Text] [Related]
52. Accuracy of Disclosed Financial Relationships between Radiologists and Industry at the 2018 RSNA Annual Meeting.
Speir EJ; Hills NK; Lokken RP
Radiology; 2021 Aug; 300(2):433-435. PubMed ID: 34100685
[No Abstract] [Full Text] [Related]
53. A better Code of Conduct.
Williams R
Can Fam Physician; 2005 May; 51():708-9. PubMed ID: 15934276
[No Abstract] [Full Text] [Related]
54. Conflict of interest and its significance in science and medicine.
Pope John Paul II
Natl Cathol Bioeth Q; 2002; 2(2):315-7. PubMed ID: 12854588
[No Abstract] [Full Text] [Related]
55. [The influence of the pharmaceutical industry in patient organisations].
Vermeulen M; Bouma J
Ned Tijdschr Geneeskd; 2007 Nov; 151(44):2432-4. PubMed ID: 18064861
[TBL] [Abstract][Full Text] [Related]
56. [Scientific societies and their economic relationship with the companies. Situation in Spain].
Ruano-Ravina A
Med Clin (Barc); 2012 May; 138(14):614-6. PubMed ID: 22440141
[No Abstract] [Full Text] [Related]
57. Commentary: Addressing corporate influence through ethical guidelines.
Greenland S
Int J Epidemiol; 2008 Feb; 37(1):57-9; discussion 65-8. PubMed ID: 18245052
[No Abstract] [Full Text] [Related]
58. Current controversies in prenatal diagnosis 4: does industry-sponsorship accelerate or hinder the pace of research?
Sterckx S; Worthington G; Van Steirteghem A
Prenat Diagn; 2011 Mar; 31(3):244-5. PubMed ID: 21374638
[No Abstract] [Full Text] [Related]
59. Conflicts of interest matter and awareness is needed.
Vineis P; Saracci R
J Epidemiol Community Health; 2015 Oct; 69(10):1018-20. PubMed ID: 25636323
[TBL] [Abstract][Full Text] [Related]
60. Should drug companies be allowed to sponsor Cochrane reviews?
Moynihan R
CMAJ; 2003 Nov; 169(11):1201. PubMed ID: 14638670
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
